This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Floats Vioxx Re-Stock

Merck (MRK - Get Report) has suggested a powerful antidote for its sales sickness.

The company may reverse the biggest drug recall in history. In a surprising announcement late Thursday, a Merck executive hinted that the company may begin reselling Vioxx -- a painkiller that generated billions of dollars in sales -- after yanking it off the market last September due to cardiac risks.

Peter Kim, the company's director of research, said that Merck originally pulled the drug because it thought safer alternatives were available. However, research since the withdrawal has identified similar risks with other so-called Cox-2 inhibitors like two -- Bextra and Celebrex -- manufactured by rival Pfizer (PFE - Get Report).

Kim's statement came on the second day of a special three-day hearing held by government advisers who will help decide the fate of the entire class of Cox-2 drugs. Ultimately, the Food and Drug Administration could rule to withdraw all of the drugs or -- most believe -- require them to carry much stronger warning labels.

The possibility that Vioxx may rejoin the group of available Cox-2 inhibitors clearly took the public by surprise. Shares of Merck stock jumped 4.3% to $30.09 in premarket trade on Friday.

Still, analysts tend to doubt that Vioxx will actually reappear on pharmacy shelves. And even if it does, some say, demand for the once-popular painkiller will never be what it once was. If anything, they feel, the move would help Merck more in the courtroom -- where the company faces a slew of product liability lawsuits -- than in the ordinary course of business.

"While a reintroduction of Vioxx would be a surprising outcome in a number of ways, we believe that one of the greatest benefits would likely be on the legal side -- even more than any financial impact," wrote Morgan Stanley analyst Jami Rubin, who has an equal-weight rating on the stock. "If, even after all of the intensive scrutiny of recent months, the panel concluded that the overall risk/benefit profile for Vioxx supported marketing of the drug to certain populations, we believe this could help vindicate the company's -- and FDA's -- decision not to withdraw the drug earlier."

That said, Rubin believes the chance for a Vioxx relaunch is "less than 10%." Other analysts are similarly pessimistic.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $49.03 0.00%
PFE $29.36 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs